Clines Gregory A, Guise Theresa A
Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia, Charlottesville, VA 22908-1419, USA.
Clin Adv Hematol Oncol. 2004 May;2(5):295-302.
Alterations in bone architecture and mineral metabolism are common complications of malignancy. Cancers such as breast, prostate, and lung can affect the skeleton either indirectly through the elaboration of factors that act to disrupt normal calcium homeostasis at the level of the kidney and bone; or directly via secondary spread of tumor to bone. Although the pathophysiology of these skeletal complications is diverse, it is clear that the osteoclast and osteoblast are not just bystanders but are active participants in the development and progression of hypercalcemia and bone metastasis. Our understanding of the molecular mechanisms of metastasis leading to tumor cell escape, homing, adhesion, and secondary growth in a hospitable environment are evolving. Treatment modalities aimed at not only reducing tumor burden but altering the skeletal response to tumor have shown benefit. Newer generation bisphosphonates are quite effective in controlling hypercalcemia of malignancy and have been shown to delay progression of skeletal metastases. Clearly, cancer-associated bone morbidity remains a major public health problem. To improve therapy and prevention it is important to understand the pathophysiology of the effects of cancer on bone. This review will detail scientific advances regarding this area.
骨骼结构和矿物质代谢的改变是恶性肿瘤常见的并发症。乳腺癌、前列腺癌和肺癌等癌症可通过分泌作用于肾脏和骨骼水平以破坏正常钙稳态的因子间接影响骨骼;或通过肿瘤向骨骼的继发性扩散直接影响骨骼。尽管这些骨骼并发症的病理生理学各不相同,但很明显破骨细胞和成骨细胞不仅是旁观者,而且是高钙血症和骨转移发生发展的积极参与者。我们对转移分子机制的理解,即肿瘤细胞如何在适宜环境中逃逸、归巢、黏附并二次生长,正在不断发展。旨在不仅减轻肿瘤负担而且改变骨骼对肿瘤反应的治疗方式已显示出益处。新一代双膦酸盐在控制恶性肿瘤高钙血症方面非常有效,并已被证明可延缓骨转移的进展。显然,癌症相关的骨病仍然是一个重大的公共卫生问题。为了改善治疗和预防,了解癌症对骨骼影响的病理生理学很重要。本综述将详细阐述该领域的科学进展。